Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222030 | 0.88 | MEN1 (0.49) | MEN1KMT2AALDH1A1TSHRKDM4E | |
| SCHEMBL6201157 | 0.87 | KDM4E (0.54) | MEN1KMT2AALDH1A1TSHRKDM4E | |
| SCHEMBL220786 | 0.86 | CYP1A2 (0.57) | MEN1KMT2AALDH1A1TSHRKDM4E | |
| SCHEMBL220727 | 0.86 | HTT (0.48) | ALDH1A1TSHRKDM4EDRD2DRD4 | |
| SCHEMBL6312218 | 0.82 | HRH3 (0.52) | MEN1KMT2AALDH1A1HRH3DRD2 | |
| SCHEMBL6173652 | 0.78 | KMT2A (0.42) | MEN1KMT2AALDH1A1TSHRKDM4E | |
| SCHEMBL4421520 | 0.76 | ALDH1A1 (0.50) | ALDH1A1KDM4ETDP1HRH3POLB | |
| SCHEMBL13284339 | 0.76 | MEN1 (0.79) | MEN1KMT2AALDH1A1TSHRKDM4E | |
| SCHEMBL7442877 | 0.75 | TSHR (0.42) | ALDH1A1TSHRKDM4ETDP1L3MBTL1 | |
| SCHEMBL2343088 | 0.75 | ACHE (0.47) | ALDH1A1TSHRKDM4EL3MBTL1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088928-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | claimed |
| EP-1909910-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | claimed |
| EP-1910380-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | Sirtris Pharmaceuticals, Inc. (US) | 2008-04-16 | — | — | EP | claimed |
| WO-2007019417-A1 | OXAZOLOPYRIDINE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | claimed |
| WO-2007019416-A1 | BENZIMIDAZOLE DERIVATIVES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | claimed |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-08-02 | — | — | US | disclosed |
| EP-2468752-A1 | Thiazolopyridine derivatives as sirtuin-modulators | Sirtris Pharmaceuticals, Inc. (US) | 2012-06-27 | — | — | EP | disclosed |
| US-8178536-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8163908-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120022254-A1 | SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-8093401-B2 | Silent Information Regulators; aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting , increased mitochondrial activity, inflammation, cancer, and/or flushing; increased lifespan specially in mutant sir2 strains; imidazo[1,2-a]pyridine drivatives | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-8088928-B2 | Sirtuin modulating compounds | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2007019346-A1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019344-A1 | IMIDAZO [2,1-B] THIAYOLE DERIVATIVES AS SIRTUIN MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-02-15 | — | — | US | disclosed |
| EP-1027051-B1 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2005-01-05 | — | — | EP | disclosed |
| US-6391901-B1 | Thrombin inhibitors | ELI LILLY AND COMPANY | 2002-05-21 | — | — | US | disclosed |
| EP-1027051-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2001-03-07 | — | — | EP | disclosed |
| EP-1027051-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1998048804-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037809-A1 | histone deacetylase inhibitors, used for treating preventing diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood disorders, inflammation, cancer, and/or hot flashes | SIRT1, SIRT3, SIRT2 | MEN1 3453/4885KMT2A 137/4885ALDH1A1 844/4885 |
| US-20120022254-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | MEN1 3137/4885KMT2A 1087/4885ALDH1A1 1825/4885 |
| US-20120197013-A1 | SIRTUIN MODULATING COMPOUNDS | SIRT1, SIRT3, SIRT2 | MEN1 3137/4885KMT2A 1087/4885ALDH1A1 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.